Yuankai Shi (Shiyu Jiang)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Toll Like Receptor

Small Cell Lung Cancer

Top Venues

Targeted oncology

Journal of hematology & oncology

Annals of hematology

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Zucheng Xie, Yan Qin, Xinrui Chen, Sheng Yang, Jianliang Yang, Lin Gui, Peng Liu, Xiaohui He, Shengyu Zhou, Changgong Zhang, Le Tang, Yuankai Shi
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Targeted oncology 19 (3) (2024)
Zucheng Xie, Yan Qin, Xinrui Chen, Sheng Yang, Jianliang Yang, Lin Gui, Peng Liu, Xiaohui He, Shengyu Zhou, Changgong Zhang, Le Tang, Yuankai Shi
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Targeted oncology (2024)
Zucheng Xie, Yan Qin, Xinrui Chen, Sheng Yang, Jianliang Yang, Lin Gui, Peng Liu, Xiaohui He, Shengyu Zhou, Changgong Zhang, Le Tang, Yuankai Shi
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Targeted oncology 19 (3) (2024)
Liliang Huang, Yuankai Shi, Yuan-Kai Shi
Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data. Future oncology (London, England) 18 (14) (2022)
Xin Liu, Yuankai Shi, Huijie Wang, Xianghua Wu, Wangjun Yan, Yong Chen, Yu Xu, Chunmeng Wang, Weiqiang Yao, Jian Wang, Lin Yu, Jiashun Miao, Hao Chen, Jing Xia, Mengli Huang, Xiaowei Zhang, Zhiguo Luo
Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft tissue sarcoma: a prospective, single-arm phase II study. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu, Yuankai Shi
First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. Journal of hematology & oncology 13 (1) (2020)
Haizhu Chen, Yan Qin, Jianliang Yang, Peng Liu, Changgong Zhang, Xiaohui He, Shengyu Zhou, Sheng Yang, Lin Gui, Liqiang Zhou, Yan Sun, Yuankai Shi
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. Annals of hematology 99 (12) (2020)
Yuankai Shi, Xuezhi Hao, Junling Li, Xingsheng Hu, Zefen Xiao, Hongyu Wang, Yan Wang, Yan Sun, Yuankai Shi
Small cell lung cancer in the young: Characteristics, diagnosis and outcome data. The clinical respiratory journal 13 (2) (2019)
Yongkun Sun, Lin Yang, Xuezhi Hao, Yutao Liu, Jinwen Zhang, Zhiqiang Ning, Yuankai Shi
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. Journal of hematology & oncology 12 (1) (2019)
Puyuan Xing, Xiaohong Han, Sha Wang, Yutao Liu, Sheng Yang, Xuezhi Hao, Yan Wang, Peng Liu, Junling Li, Lin Wang, Lianpeng Chang, Yanfang Guan, Zhishang Zhang, Di Wu, Jiarui Yao, Xin Yi, Yuankai Shi
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. Journal of cellular and molecular medicine 23 (10) (2019)
Shiyu Jiang, Peng Liu, Sheng Yang, Jianliang Yang, Dawei Wu, Hong Fang, Yan Qin, Shengyu Zhou, Jianping Xu, Yongkun Sun, Hongnan Mo, Lin Gui, Puyuan Xing, Bo Lan, Bo Zhang, Le Tang, Yan Sun, Yuankai Shi
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. BMJ open 9 (5) (2019)
Yuankai Shi, Jin Li, Jianming Xu, Yan Sun, Liwei Wang, Ying Cheng, Wei Liu, Guoping Sun, Yigui Chen, Li Bai, Yiping Zhang, Xiaohui He, Yi Luo, Zhehai Wang, Yunpeng Liu, Qiang Yao, Yuhong Li, Shukui Qin, Xiaohua Hu, Feng Bi, Rongsheng Zheng, Xuenong Ouyang
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. Cancer communications (London, England) 39 (1) (2019)